专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2311801A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor 审中-公开
标题翻译：用于疾病的治疗，其对多巴胺D 3受体的调节有反应的，合适的6-氨基（氮杂）茚满化合物
公开(公告)号：EP2311801A1
公开(公告)日：2011-04-20
申请号：EP10183356.4
申请日：2005-10-14
申请人： Abbott GmbH & Co. KG
发明人： Drescher, Karla , Haupt, Andreas , Unger, Liliane , Turner, Sean C. , Braje, Wilfried , Grandel, Roland
IPC分类号： C07C311/21 , C07D221/06 , C07D239/38 , C07D333/34 , C07D401/12 , C07D409/12 , A61K31/18 , A61K31/506 , A61P25/18
CPC分类号： C07D239/38 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2602/08 , C07D221/06 , C07D333/34 , C07D401/12 , C07D409/12
摘要： The present invention relates to 6-amino(aza)indane compound of the formula I

and the physiologically tolerated acid addition salts of these compounds.
The invention also relates to pharmaceutical compositions comprising at least one compound of the formula I or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula I or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及6-氨基（氮杂）茚满I和生理上容许的化合物本文的酸加成盐的式I化合物。因此，本发明涉及药物组合物，其包括下式的至少一种式I化合物或其药学上可接受的盐以及一种用于治疗医学病症的治疗敏感的用多巴胺D 3受体配体有效量的以，所述方法包括给予一个方法式I或其药学上可接受的盐的至少一种化合物。

2. 发明公开

EP1484330A1 Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 有权
标题翻译： Triazolfürdie Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten
公开(公告)号：EP1484330A1
公开(公告)日：2004-12-08
申请号：EP04013358.9
申请日：2004-06-07
申请人： Abbott GmbH & Co. KG
发明人： Haupt, Andreas , Grandel, Roland , Braje, Wilfried , Geneste, Hervé , Drescher, Karla , Starck, Dorothea , Teschendorf, Hans-Jürgen
IPC分类号： C07D403/12 , A61K31/506 , A61P25/18
CPC分类号： C07D403/12
摘要： The invention relates to triazole compounds of the general formula I
wherein
R 1 is hydrogen or methyl, and
R 2 is C 3 -C 4 alkyl or C 1 -C 2 fluoroalkyl,
as well as the physiologically tolerated acid addition salts of these compounds.
The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.
摘要翻译：本发明涉及通式I 的三唑化合物，其中R 1为氢或甲基，R 2为C 3 -C 4烷基或C 1 -C 2氟代烷基，以及生理学上可耐受的酸加成盐这些化合物。本发明还涉及包含至少一种式I的三唑化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3的病症的方法受体拮抗剂或多巴胺D3激动剂，所述方法包括向有需要的受试者施用有效量的至少一种式III的三唑化合物或生理学上耐受的酸加成盐。

3. 发明公开

EP2371814A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 审中-公开
标题翻译： Aminoethylaromatische化合物用于病症的治疗对多巴胺D 3受体调节有反应的
公开(公告)号：EP2371814A1
公开(公告)日：2011-10-05
申请号：EP11158071.8
申请日：2005-10-14
申请人： Abbott GmbH & Co. KG
发明人： Drescher, Karla , Haupt, Andreas , Unger, Liliane , Turner, Sean Colm , Braje, Wilfried , Grandel, Roland
IPC分类号： C07C311/29 , C07C311/21 , C07D213/76 , C07D207/09 , C07C317/22 , C07C317/14 , A61K31/18 , A61K31/44 , A61P25/18
CPC分类号： C07D213/76 , C07C311/21 , C07C311/29 , C07C2601/02 , C07D207/09
摘要： The present invention relates to aromatic compounds of the formula I

wherein the variables have the definitions given in the claims and description.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及到我worin变量具有权利要求书和说明书中给出的定义的式的芳族化合物。因此，本发明涉及使用式I化合物或用于制备用于医学病症易于与多巴胺D 3受体配体治疗的治疗药物组合物的药学上可接受的盐。

4. 发明公开

EP2332543A1 Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor 审中-公开
标题翻译：四氢苯并吖庚因和多巴因-D3-调节剂的调制
公开(公告)号：EP2332543A1
公开(公告)日：2011-06-15
申请号：EP10193184.8
申请日：2004-12-17
申请人： Abbott GmbH & Co. KG
发明人： Braje, Wilfried , Haupt, Andreas , Lubisch, Wilfried , Grandel, Roland , Drescher, Karla , Geneste, Hervé , Unger, Liliane , Sauer, Daryl
IPC分类号： A61K31/55 , C07D223/16 , A61P25/00 , C07D409/12
CPC分类号： C07D223/16 , A61K31/55 , C07D409/12
摘要： The invention relates to tetrahydrobenzazepines of the general formula I

in which the variables Ar, A, B, Y, R 1 and R 2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides.
The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to a compound according to the present invention for use in treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.
摘要翻译：本发明涉及通式I的四氢苯并吖庚因，其中变量Ar，A，B，Y，R 1和R 2具有权利要求1中所示的含义，以及这些化合物的N-氧化物，生理耐受酸这些化合物的加成盐和N-氧化物的生理上耐受的酸加成盐。本发明还涉及药物组合物，其包含至少一种式I的四氢苯并氮杂化合物，I的物理耐受的酸加成盐，式I化合物的N-氧化物和/或其物理上耐受的酸加成盐 I的N-氧化物，并且进一步用于本发明化合物，用于治疗有利于多巴胺D 3受体拮抗剂或多巴胺D 3激动剂的病症。根据本发明的化合物优选可用于治疗中枢神经系统疾病如精神分裂症和抑郁症以及治疗肾功能障碍。

5. 发明授权

EP1484330B1 Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 有权
标题翻译：三唑对多巴胺D 3受体反应性疾病的调制处理
公开(公告)号：EP1484330B1
公开(公告)日：2005-10-26
申请号：EP04013358.9
申请日：2004-06-07
申请人： Abbott GmbH & Co. KG
发明人： Haupt, Andreas , Grandel, Roland , Braje, Wilfried , Geneste, Hervé , Drescher, Karla , Starck, Dorothea , Teschendorf, Hans-Jürgen
IPC分类号： C07D403/12 , A61K31/506 , A61P25/18
CPC分类号： C07D403/12

6. 发明公开

EP2439203A1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 有权
标题翻译： Arylsulfonylmethyl-或芳基磺酰胺取代的芳族化合物用于治疗疾病有关多巴胺D 3受体的调节治疗
公开(公告)号：EP2439203A1
公开(公告)日：2012-04-11
申请号：EP12150319.7
申请日：2005-10-14
申请人： Abbott GmbH & Co. KG
发明人： Drescher, Karla , Haupt, Andreas , Unger, Liliane , Turner, Sean, Colm , Braje, Wilfried , Grandel, Roland , Henry, Christophe
IPC分类号： C07D311/04 , C07D215/38 , C07C211/19 , A61K31/13 , A61K31/47 , A61K31/35 , A61P25/16 , C07C311/21 , C07C311/29 , C07C311/44 , C07D207/10 , C07D211/10 , C07D239/84 , C07D263/32 , C07D277/82 , C07D413/04 , C07D491/04
CPC分类号： C07C311/21 , C07C311/29 , C07C311/44 , C07C2601/02 , C07C2602/10 , C07D207/10 , C07D211/10 , C07D215/38 , C07D239/84 , C07D263/32 , C07D277/82 , C07D311/04 , C07D413/04 , C07D491/04
摘要： The present invention relates to aromatic compounds of the formula I

wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ;
X is N or CH;
Y is O, S, -CH=N-, -CH=CH- or -N=CH-;
A is CH 2 , O or S;
E is CR 6 R 7 or NR 3 ;
R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl;
R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1a and R 2a together are (CH 2 ) n with n being 2 or 3;
R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ;
R 3 is H or C 1 -C 4 -alkyl;
R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl;
and the physiologically tolerated acid addition salts thereof.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

7. 发明公开

EP2311803A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 审中-公开
标题翻译：为DopaminD3受体响应的疾病的调制的治疗杂环化合物
公开(公告)号：EP2311803A1
公开(公告)日：2011-04-20
申请号：EP10183342.4
申请日：2005-10-14
申请人： Abbott GmbH & Co. KG
发明人： Drescher, Karla , Haupt, Andreas , Unger, Liliane , Turner, Sean C. , Braje, Wilfried , Grandel, Roland , Henry, Christophe , Backfisch, Gisela , Beyerbach, Armin , Lubisch, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/40 , A61K31/445 , A61P25/16 , A61P25/18 , A61P25/24
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I)

wherein
n
is 0, 1 or 2;
G
is CH 2 or CHR 3 ;
R 1
is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl;
R 2 R 3 and R 4
are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
A
is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ;
E
is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl;
Ar
is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description;

and physiologically tolerated acid addition salts thereof.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）的worin化合物n是0,1或2; G为CH 2或CHR 3; R 1为H，C 1 -C 6烷基，C 1 -C 6烷基被C 3 -C 6环烷基取代，C 1 -C 6羟基烷基，氟化的C 1 -C 6烷基，C 3 - C 6环烷基，氟化的C 3 -C 6环烷基，C 3 -C 6链烯基，氟化的C 3 -C 6链烯基，甲酰基，乙酰基或丙酰基; R 2 R 3和R 4，彼此独立地为H，甲基，氟甲基，二氟甲基，或三氟甲基的; A为亚苯基，吡啶基，嘧啶基，吡嗪基，哒嗪或噻吩，其可被选自卤素，甲基，甲氧基和CF 3中选择的一种或多种取代基所substituiertem; E为NR 5或CH 2，worin R 5为H或C 1 -C 3烷基; Ar是环状基团选自苯基中选择，5-或6-元杂芳基基团，其包括作为环成员1，2或选自N，O和S的和稠合的饱和或不饱和5的苯基环中的杂原子3 - 或6-元碳环或杂环，其中所述杂环包含作为环成员1，选自N，O和S和/或1,2或3个含杂原子基团中选择2或3的杂原子各自独立地选自NR 8中选择，其中R 8是H，C 1 -C 4烷基，氟代C 1 -C 4烷基，C 1 -C 4烷基羰基或氟化的C 1 -C 4烷基羰基，并且其中该环状基团Ar可以携带1， 2个或3个取代基R a，worin变量R a具有在权利要求和说明书中给出的含义; 和生理上容许的其酸加成盐。因此，本发明涉及使用式I化合物或用于制备用于医学病症易于与多巴胺D 3受体配体治疗的治疗药物组合物的药学上可接受的盐。

8. 发明公开

EP2311802A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 审中-公开
标题翻译：杂环化合物，以响应治疗与受体Dopamind3疾病的调制
公开(公告)号：EP2311802A1
公开(公告)日：2011-04-20
申请号：EP10183328.3
申请日：2005-10-14
申请人： Abbott GmbH & Co. KG
发明人： Drescher, Karla , Haupt, Andreas , Unger, Liliane , Turner, Sean C. , Braje, Wilfried , Grandel, Roland , Henry, Christophe , Backfisch, Gisela , Beyerbach, Armin , Lubisch, Wilfried
IPC分类号： C07D207/09 , C07D401/12 , C07D405/12 , C07D409/12 , C07D401/04 , C07D403/04 , C07D413/12 , C07D205/04 , C07D413/10 , C07D413/14 , C07D211/28 , A61K31/397 , A61K31/40 , A61K31/445 , A61P25/16 , A61P25/18 , A61P25/24
CPC分类号： C07D413/14 , C07D205/04 , C07D207/09 , C07D211/28 , C07D401/04 , C07D401/12 , C07D403/04 , C07D405/12 , C07D409/12 , C07D413/10 , C07D413/12
摘要： The invention relates to compounds of the formula (I)

wherein
n is 0,1 or 2;
G is CH 2 or CHR 3 ;
R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl;
R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ;
E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl;
Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 3 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description;

and physiologically tolerated acid addition salts thereof.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式（I）worin n为0.1或2的化合物; G为CH 2或CHR 3; R 1为H，C 1 -C 6烷基，C 1 -C 6烷基被C 3 -C 6环烷基取代，C 1 -C 6羟基烷基，氟化的C 1 -C 6烷基，C 3 - C 6环烷基，氟化的C 3 -C 6环烷基，C 3 -C 6链烯基，氟化的C 3 -C 6链烯基，甲酰基，乙酰基或丙酰基; R 2，R 3和R 4，彼此独立地为H，甲基，氟甲基，二氟甲基，或三氟甲基的; A为亚苯基，吡啶基，嘧啶基，吡嗪基，哒嗪或噻吩，其可被选自卤素，甲基，甲氧基和CF 3中选择的一种或多种取代基所substituiertem; E为NR 5或CH 2，worin R 5为H或C 1 -C 3烷基; Ar是环状基团选自苯基中选择，5-或6-元杂芳基基团，其包括作为环成员1，2或选自N，O和S的和稠合的饱和或不饱和5的苯基环中的杂原子3 - 或6-元碳环或杂环，其中所述杂环包含作为环成员1，选自N，O和S和/或1,2或3个含杂原子基团中选择2或3的杂原子各自独立地选自NR 8中选择，当R 3为H，C 1 -C 4烷基，氟代C 1 -C 4烷基，C 1 -C 4烷基羰基或氟化的C 1 -C 4烷基羰基，并且其中该环状基团Ar可以携带1， 2个或3个取代基R a，worin变量R a具有在权利要求和说明书中给出的含义; 和生理上容许的其酸加成盐。因此，本发明涉及使用式I化合物或用于制备用于医学病症易于与多巴胺D 3受体配体治疗的治疗药物组合物的药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式